| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443431 | European Journal of Cancer | 2014 | 10 Pages |
Abstract
Pemetrexed + erlotinib treatment significantly improved PFS, OS and TTTF in 2nd line non-squamous NSCLC and was associated with an increase in grade 3/4 toxicities compared with pemetrexed alone.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christian Dittrich, Zsolt Papai-Szekely, Nuria Vinolas, Christer Sederholm, Joerg T. Hartmann, Dirk Behringer, Gbenga Kazeem, Durisala Desaiah, Monika I. Leschinger, Joachim von Pawel,